GFAP and schizophrenia: Moreover, multiple injections of the NMDA receptor antagonist that causes schizophrenia-like symptoms has led to increase in the level of GFAP in the hippocampus of rats (Yu et al., 2015) and in the medial prefrontal cortex of mice (Gomes et al., 2015).